Simultaneously targeting TIGIT, PD-1 and PVRIG immune checkpoint combination therapy to complete the first case of administration

On July 19, 2021, Compugen announced that in patients with advanced solid tumors, the Phase 1/2 dose escalation trial of its triple therapy combination has completed the first patient's administration

PVRIG is a new B7/CD28-like immune checkpoint protein, and PVRL2 is the ligand of PVRIG

TIGIT is an inhibitory receptor protein mainly expressed on the surface of T cells and natural killer (NK) cells.

In addition, Compugen has determined that PVRIG and TIGIT are key parallel and complementary inhibitory pathways in the DNAM pathway

▲Blocking PVRIG and TIGIT can produce synergistic effects (picture source: Compugen official website)

COM701 is a humanized antibody that can bind to PVRIG with high affinity, thereby blocking its interaction with the ligand PVRL2

BMS-986207 is a Bristol-Myers Squibb antibody drug under development that targets TIGIT.

Note: The original text has been deleted

Reference materials:

[1] Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207.